Group 1: Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [2] - The company holds an exclusive license for AGAMREE® (vamorolone), a dissociative steroid, which is being investigated as an alternative to standard corticosteroids for treating Duchenne muscular dystrophy (DMD) [2] - AGAMREE has received regulatory approvals in multiple regions, including the U.S., EU, UK, Switzerland, China, Hong Kong, and Canada [2] Group 2: Recent Developments - Santhera Pharmaceuticals has appointed Stifel Nicolaus Europe Limited as a corporate finance advisor, focusing on capital markets and international institutional investors [1] - Octavian AG will continue to act as a corporate finance advisor alongside Stifel to broaden investor reach [1] Group 3: Licensing Agreements - Santhera has out-licensed the rights to AGAMREE to various companies: Catalyst Pharmaceuticals for North America, Sperogenix Therapeutics for China and certain Southeast Asian countries, and Nxera Pharma for Japan, South Korea, Australia, and New Zealand [2]